Incretin effect of glucagon-like peptide 1 receptor agonist is preserved in presence of ABCC8/SUR1 mutation in β-cell

Diabetes Care. 2012 Nov;35(11):e76. doi: 10.2337/dc12-0535.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP-Binding Cassette Transporters / genetics*
  • Adult
  • Diabetes Mellitus / drug therapy
  • Exenatide
  • Female
  • Glucagon-Like Peptide 1 / metabolism
  • Glucagon-Like Peptide-1 Receptor
  • Glucose Tolerance Test
  • Humans
  • Incretins / therapeutic use*
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism*
  • Male
  • Middle Aged
  • Mutation
  • Peptides / therapeutic use
  • Potassium Channels, Inwardly Rectifying / genetics*
  • Receptors, Drug / genetics*
  • Receptors, Glucagon / agonists*
  • Sulfonylurea Receptors
  • Venoms / therapeutic use

Substances

  • ABCC8 protein, human
  • ATP-Binding Cassette Transporters
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Incretins
  • Peptides
  • Potassium Channels, Inwardly Rectifying
  • Receptors, Drug
  • Receptors, Glucagon
  • Sulfonylurea Receptors
  • Venoms
  • Glucagon-Like Peptide 1
  • Exenatide